Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment

by admin | April 2, 2025 | Latest news, Press Releases

First subjects dosed in double-blind, placebo-controlled trial assessing AT-7687’s safety, tolerability, pharmacokinetics, and metabolic effects in healthy lean subjects and subjects living with obesity With strong genetic and clinical validation, AT-7687 aims to...

Experienced Industry Leader Dr. Joerg Moeller Appointed as Chief Executive Officer of Antag Therapeutics

by admin | January 8, 2025 | Latest news, Press Releases

Former Head of Global R&D at Bayer AG and an exceptional leader with a wealth of experience across biopharma Pivotal time of transition as the company prepares to start clinical development of its first in-class lead candidate, AT-7687 in obesity AT-7687 offers a...

Antag Therapeutics Announces €80 Million Series A Financing

by admin | December 4, 2024 | Latest news, Press Releases

Round led by Versant Ventures with participation from founding investor Novo Holdings and new investors SR One, Dawn Biopharma and Pictet Entering Phase I testing for next-generation weight loss therapy by antagonizing GIPR Antag Therapeutics, a next-generation...

Antag Therapeutics Announces FDA Clearance ofInvestigational New Drug (IND) Application for LeadMolecule, AT-7687

by admin | October 9, 2024 | Latest news

Antag Therapeutics, a leading biopharmaceutical company focused on targeting the Glucose-Dependent Insulinotropic Polypeptide (GIP) receptor to pioneer novel treatments for obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted its...

Antag Therapeutics appoints Dr. Christine T. Fischette to its Board of Directors

by admin | July 15, 2021 | Latest news

Brings substantial industry expertise and strategic focus for sustained company development Antag Therapeutics ApS, a privately-held biotechnology company focused on the development of novel treatments for dietary-related diseases with obesity as its prime focus,...